Skip to content

To keep going please Log in.

or

By submitting my information, I agree to the Privacy Policy and Terms of Service.

To keep going please Log in.

or

By submitting my information, I agree to the Privacy Policy and Terms of Service.

To keep going please Log in.

or

By submitting my information, I agree to the Privacy Policy and Terms of Service.

To keep going please Log in.

or

By submitting my information, I agree to the Privacy Policy and Terms of Service.

IDYA IDEAYA Biosciences, Inc. Common Stock
$30.27 0.00% 0.00
Notify me if price changes either direction
Interactive Brokers Logotype

Buy IDYA stocks now with Interactive Brokers – the most advanced investment platform

Contents
  • Performance
  • Key stats
  • Financials
  • US politician trades
Loading

Key Stats

Market cap. 2.7B
Enterprise value 1.9B
Trailing PE -9.0089287076678
Forward PE -8.499419
PEG Ratio 0.027719780638978
Enterprise to EBITDA -9.18
Enterprise to revenue 8.816
Price to book MRQ 2.429959
Price to sales TTM 12.352152

Financials

Fiscal Year Ends 2024-12-31
Most Recent Quarter (MRQ) 2025-09-30
Revenue (TTM) 214.8M
EBITDA -206330000
Diluted EPS TTM -1.89
Total Cash (MRQ) 786.9M
Current ratio (MRQ) 12.443
Operating Cash Flow (TTM) -102257000

IDYA trades by the US politicians

Percentage
0% 0 sells
100% 0 buys
Amount
$0 0 sells
$0 0 buys
In the last 0 months

Recent IDYA News

Home

IMPORTANT NOTICE

Finbold is a news and information website. This Site may contain sponsored content, advertisements, and third-party materials, for which Finbold expressly disclaims any liability.

RISK WARNING: Cryptocurrencies are high-risk investments and you should not expect to be protected if something goes wrong. Don’t invest unless you’re prepared to lose all the money you invest. (Click here to learn more about cryptocurrency risks.)

By accessing this Site, you acknowledge that you understand these risks and that Finbold bears no responsibility for any losses, damages, or consequences resulting from your use of the Site or reliance on its content. Click here to learn more.